Abstract
A randomized double-blind study was undertaken comparing the therapeutic efficacy of pyrisuccideanol maleate (Nadex) and placebo in sixteen general practices, involving a total of 100 patients presenting with mild to moderate depression. The trial duration period was 6 weeks with assessments being made initially, and at 4 and 6 weeks. A consistently higher proportion of those treated with Nadex demonstrated an improvement in their symptoms as compared to those treated with placebo and some of the differences proved to be statistically significant. Nadex was also observed to be well tolerated.
Get full access to this article
View all access options for this article.